Cargando…

Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer

Prediction of drug combinations that effectively target cancer cells is a critical challenge for cancer therapy, in particular for triple-negative breast cancer (TNBC), a highly aggressive breast cancer subtype with no effective targeted treatment. As signalling pathway networks critically control c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shin, Sung-Young, Müller, Anna-Katharina, Verma, Nandini, Lev, Sima, Nguyen, Lan K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007894/ https://www.ncbi.nlm.nih.gov/pubmed/29920512 http://dx.doi.org/10.1371/journal.pcbi.1006192

Ejemplares similares

PYK2 negatively regulates the Hippo pathway in TNBC by stabilizing TAZ protein
por: Kedan, Amir, et al.
Publicado: (2018)

Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers
por: Linklater, Erik S., et al.
Publicado: (2016)

The AXL-PYK2-PKCα axis as a nexus of stemness circuits in TNBC
por: Khera, Lohit, et al.
Publicado: (2021)

cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer
por: Sohn, Joohyuk, et al.
Publicado: (2014)

Targeting FAK/PYK2 with SJP1602 for Anti-Tumor Activity in Triple-Negative Breast Cancer
por: Jeon, Myeongjin, et al.
Publicado: (2023)

Tyrosine Phosphorylation of Pyk2 Is Selectively Regulated by Fyn During TCR Signaling
por: Qian, Dapeng, et al.
Publicado: (1997)

MET-Pyk2 Axis Mediates Acquired Resistance to FGFR Inhibition in Cancer Cells
por: Kitowska, Kamila, et al.
Publicado: (2021)

PYK2 integrates growth factor and cytokine receptors signaling and potentiates breast cancer invasion via a positive feedback loop
por: Selitrennik, Michael, et al.
Publicado: (2015)

Mouse Modeling Dissecting Macrophage–Breast Cancer Communication Uncovered Roles of PYK2 in Macrophage Recruitment and Breast Tumorigenesis
por: Müller, Anna‐Katharina, et al.
Publicado: (2022)

Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines
por: Simiczyjew, Aleksandra, et al.
Publicado: (2018)

Deguelin Action Involves c-Met and EGFR Signaling Pathways in Triple Negative Breast Cancer Cells
por: Mehta, Rajeshwari, et al.
Publicado: (2013)

SH003 and Docetaxel Show Synergistic Anticancer Effects by Inhibiting EGFR Activation in Triple-Negative Breast Cancer
por: Choi, Yu-Jeong, et al.
Publicado: (2022)

Pyk2 for perfect bones
por: LeBrasseur, Nicole
Publicado: (2007)

Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells
por: Panayotopoulou, Effrosini G., et al.
Publicado: (2017)

EGFR signaling pathway occupies an important position in cancer‐related downstream signaling pathways of Pyk2
por: Shen, Ting, et al.
Publicado: (2019)

Targeting EGFR in Triple Negative Breast Cancer
por: Ueno, Naoto T., et al.
Publicado: (2011)

Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6
por: YI, YONG WEON, et al.
Publicado: (2015)

Role of Pyk2 in Human Cancers
por: Shen, Ting, et al.
Publicado: (2018)

Co-dependency for MET and FGFR1 in basal triple-negative breast cancers
por: Sung, Vanessa Y. C., et al.
Publicado: (2021)

Impact of the Whole Genome Duplication Event on PYK Activity and Effects of a PYK1 Mutation on Metabolism in S. cerevisiae
por: Chen, Hong, et al.
Publicado: (2021)

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
por: Presutti, Dario, et al.
Publicado: (2015)

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation
por: Nakade, Junya, et al.
Publicado: (2014)

MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition
por: Ortiz-Zapater, Elena, et al.
Publicado: (2017)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

Deep graph embedding for prioritizing synergistic anticancer drug combinations
por: Jiang, Peiran, et al.
Publicado: (2020)

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
por: Guerrab, Abderrahim El, et al.
Publicado: (2016)

Targeted Inhibition of FAK, PYK2 and BCL-XL Synergistically Enhances Apoptosis in Ovarian Clear Cell Carcinoma Cell Lines
por: Yoon, Heejei, et al.
Publicado: (2014)

Novel Role of Src in Priming Pyk2 Phosphorylation
por: Zhao, Ming, et al.
Publicado: (2016)

Convergent Effects of Resveratrol and PYK2 on Prostate Cells
por: Conte, Andrea, et al.
Publicado: (2016)

PYK2 at the Intersection of Signaling Pathways in Pancreatic Cancer
por: Means, Anna L.
Publicado: (2019)

High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer
por: Zagouri, F, et al.
Publicado: (2013)

Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer
por: Jiang, Weihua, et al.
Publicado: (2020)

EGFR/Met association regulates EGFR TKI resistance in breast cancer
por: Mueller, Kelly L, et al.
Publicado: (2010)

Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
por: Nandini, Dey, et al.
Publicado: (2021)

Triple Combination of Ascorbate, Menadione and the Inhibition of Peroxiredoxin-1 Produces Synergistic Cytotoxic Effects in Triple-Negative Breast Cancer Cells
por: Bajor, Malgorzata, et al.
Publicado: (2020)

Synergistic effects of combined cisplatin and Clinacanthus nutans extract on triple negative breast cancer cells
por: Abu Bakar, Nur Fitriyani Afiqah Binti, et al.
Publicado: (2023)

Differential prioritization of therapies to subtypes of triple negative breast cancer using a systems medicine method
por: Wathieu, Henri, et al.
Publicado: (2017)

Suppression of Pyk2 Kinase and Cellular Activities by Fip200
por: Ueda, Hiroki, et al.
Publicado: (2000)

Pyk2 promotes tumor progression in renal cell carcinoma
por: Zhao, Tangliang, et al.
Publicado: (2018)

Pyk2 Regulates MAMs and Mitochondrial Dynamics in Hippocampal Neurons
por: López-Molina, Laura, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_icbu5dn7dp02ahvcos03k9r41d